Current best evidence for clinical care (more info)
BACKGROUND: The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7% efficacy against COVID-19 in a phase 3, randomized, observer-blinded, placebo-controlled trial in the United Kingdom. The protocol was amended to include a blinded crossover; data to the end of the placebo-controlled phase are reported.
METHODS: Adults aged 18-84 years received two doses of NVX-CoV2373 or placebo (1:1) and were monitored for virologically confirmed mild, moderate, or severe COVID-19 (onset from 7 days after second vaccination). Participants who seroconverted to immunoglobulin G (IgG) against the nucleocapsid protein and did not meet criteria for symptomatic COVID-19 were classified as having asymptomatic disease. Secondary outcomes included anti-spike (S) IgG responses, wild-type virus neutralization, and T-cell responses.
RESULTS: Of 15185 participants, 13989 remained in the per-protocol efficacy population (6989 NVX-CoV2373, 7000 placebo). At a maximum of 7.5 months (median, 4.5 months) postvaccination, there were 24 cases of COVID-19 among NVX-CoV2373 recipients and 134 cases among placebo recipients, a vaccine efficacy of 82.7% (95% CI: 73.3-88.8). Vaccine efficacy was 100% (17.9-100.0) against severe disease and 76.3% (57.4-86.8) against asymptomatic disease. High anti-S and neutralization responses to vaccination were evident, together with S-protein-specific induction of interferon-? secretion in peripheral blood T cells. Incidence of serious adverse events and adverse events of special interest were similar between groups.
CONCLUSIONS: A two-dose regimen of NVX-CoV2373 conferred a high level of ongoing protection against asymptomatic, symptomatic, and severe COVID-19 through >6 months postvaccination. A gradual decrease of protection suggests that a booster dose may be indicated.
|Discipline / Specialty Area||Score|
Additional data on the safety and efficacy of the Novavax COVID-19 vaccine (adjuvanted, recombinant protein) is noteworthy for 100% efficacy in preventing severe disease in this randomized, observer-blind, placebo-controlled study. I suspect many practitioners will rely on public health vaccine recommendations rather than the independent study of this paper. However, the benefit at a median of 4.5 months of follow-up in preventing severe disease may attract attention.
Six times more cases of COVID-19 infection in placebo recipients than in vaccine recipients. The incidence of COVID-19, 1.9% in placebo recipients and 0.3% in vaccine recipients; absolute risk reduction, 1.6; number needed to vaccinate to prevent 1 case of COVID-19 is 62. The study ended in July 2021, so may not apply to current variants. No data on efficacy of booster doses.
Outstandingly well planned, analysed, and presented study.
Hello! We would like to hear about your experiences with COVID-19 EA. Are you interested in sharing feedback through a quick 10-minute survey?
Thank you for your interest! You may navigate to the survey at any time by clicking the designated button at the top of the page.
Thank you. Should you decide to participate at a later time, you can access the survey by clicking the designated button at the top of the page.